Eurofins reports EUR 103m sales in Q1 2007 (AcT)
Brussels/ Nantes, May 15, 2007
Consolidated net sales at Eurofins Scientific for the first quarter 2007 rose more than 46% from €70.1m in 2006 to €102.7m. Organic growth for the period was over 10%. Sales are up in every region and growth has been strong in some of the areas where Eurofins is developing its business, such as Scandinavia, the British Isles and the Other Countries.
This high level of growth is also due to the consolidation in Q1 2007 of companies acquired in the course of 2006 but which were not consolidated for the full year. Some of these were substantially loss-making. Overall, due to the seasonality of their activities the first quarter is traditionally the weakest for most Eurofins laboratories.
Having added laboratories in seven countries in 2006 Eurofins is now focusing on developing its Group infrastructure, leadership, finance and IT in order to prepare for future growth. With the announcement of the issue of a €100m non-dilutive hybrid instrument (see press release 11th May 2007) Eurofins has put in place a solid financing base for this further growth and considers that it is well placed to deliver on its long term target of shareholder value generation.
€ million Q1/2007 % Q1/2006 %
Benelux 9.5 9.3 8.1 11.5
British Isles 9.3 9.0 5.2 7.4
France 21.9 21.3 15.5 22.1
Germany 22.4 21.8 17.1 24.3
North America 14.5 14.1 11.0 15.6
Scandinavia 14.7 14.3 9.0 12.9
Other 10.4 10.2 4.4 6.2
Total 102.7 100.0 70.1 100.0
For further information please contact:
Investor Relations
Tel.: +32-2-769 7383
Email: ir@eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 5,000 staff in more than 70 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext exchange in Paris (ISIN FR0000038259) and the Frankfurt (WKN 910251) Stock Exchange (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).